SMi Source Lesson Anticoagulation: Health Economics and Outcomes Research

  • SMi Source lesson Anticoagulation: Health Economics and Outcomes Research has the following microlearning topics

  • 1. Introduction

    2. Overview and Estimating Healthcare Costs Attributable to AF

    3. Kim and Associates Study: National Incremental Costs Incurred by Patients with AF

    4. Kim and Associates Study: The Annual Projected National Incremental Cost of AF

    5. Total AF, Other Cardiovascular, and Noncardiovascular Costs

    6. Cost of AF from a Payer Perspective

    7. Knowledge Check: Medical Costs

    8. Knowledge Check: National Incremental Cost

    9. Overview: Strokes in AF

    10. Stroke Risk Based Upon Anticoagulation Use

    11. Cost Based Upon Anticoagulation Use

    12. Knowledge Check: Strokes

    13. Knowledge Check: Strokes in Patients with AF

    14. Overview: Antithrombotic Therapy for Atrial Fibrillation

    15. Mercaldi and Associates Study

    16. Per Patient Cost of Bleeding

    17. Ghate and Coworkers Analysis

    18. Knowledge Check: Patient Event

    19. Knowledge Check: Annual Incremental Cost

    20. Summary of Costs for AF, Stroke and Bleeding

    21. Comorbidities Commonly Associated with AF

    22. Comorbidities Commonly Associated with AF: Wu et al., 1995

    23. Comorbidities Commonly Associated with AF: Vascular Disease and CV Risk Factors

    24. Health-Related Quality of Life (HRQoL) in AF Patients

    25. Health-Related Quality of Life Studies in Atrial Fibrillation

    26. Antithrombotic Therapy for Atrial Fibrillation, Switching Warfarin Formulations, Kwong et al., 2012

    27. Kwong and Associates Study

    28. Methods Patient Population, Study Design and Endpoints

    29. Results: Patient Population

    30. Results: Health Care Resource Use Analysis

    31. Results: Health Care Resource Use Analysis, Controlled for variables

    32. Results: Health Care Cost Analysis - Unadjusted Costs

    33. Results: Health Care Cost Analysis - Generic vs. Brand-Only

    34. Conclusion: Use and Costs Associated with Switching Warfarin

    35. Knowledge Check: The Kwong Study - Patients with Highest Total Cost

    36. Knowledge Check: The Kwong Study - Patients with Highest All-Cause Hospitalization

    37. Table Summary of Kwong et. al, 2012

    38. Overview of VTE

    39. Total Cost of VTE

    40. Per Patient Cost of DVT and PE

    41. Per Patient Cost of Recurrent VTE

    42. Incremental Cost of Recurrent VTE

    43. Knowledge Check: Per Patient Expense

    44. Knowledge Check: Cost Per Patient

    45. Summary of Costs for VTE

    46. Overview and Incidence of VTE

    47. VTE Prevalence Increases with Age

    48. Projected VTE Prevalence Increases with Time

    49. Comorbidities Commonly Associated with VTE

    50. Risk Factors for VTE

    51. Risk Categories for VTE

    52. Health-Related Quality of Life (HRQoL) in VTE Patients

    53. Health-Related Quality of Life (HRQoL) in VTE Patients: Acute Deep Vein Thrombosis

    54. Health-Related Quality of Life (HRQoL) in VTE Patients: Post-Thrombotic Syndrome

    55. Cost-Effective Analyses Overview

    56. Cost-Effective Analyses (CEAs)

    57. Harrington Study: Warfarin Compared to NOACs

    58. Study Overview: Harrington et al.

    59. Methods Patient Population

    60. Methods Study Design

    61. Methods Endpoints

    62. Harrington Study: Results

    63. Harrington Study: Conclusions

    64. Knowledge Check: Cost-Effective versus Warfarin for Stroke Prevention

    65. Knowledge Check: Willingness-To-Pay Threshold

    66. Overview: Kansal Study

    67. Kansal Study: Study Overview

    68. Kansal Study: Methods and Literature Search Strategy

    69. Kansal Study: Results

    70. Results: Cost-Effectiveness of Factor Xa Inhibitors

    71. Kansal Study: Conclusions

    72. Knowledge Check: Kansal et al. 2013 Study

    73. Mahmoudi and Sobieraj Study: Overview

    74. Mahmoudi and Sobieraj Study: Study Overview

    75. Methods: Cost-Effectiveness Model

    76. Methods: Studies Included in the Analysis and Quality-of-Life Measures

    77. Methods Endpoints: Costs

    78. Results: Base-Case Analysis and Conclusion

    79. Knowledge Check: Mahmoudi and Sobieraj Study - Anticoagulation

    80. Knowledge Check: Mahmoudi and Sobieraj Study - Cost Effective

    81. Summary of Cost-Effectiveness Studies